Please use this identifier to cite or link to this item:
Title: Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates
Author: Cantón, Rafael
Morrissey, Ian
Vila Estapé, Jordi
Tato, Marta
García Castillo, María
López, Yuly
Gargallo Viola, Domingo
Zsolt, Ilonka
Keywords: Malalties bacterianes
Malalties de la pell
Bacterial diseases
Skin diseases
Issue Date: 1-May-2018
Publisher: Future Medicine
Abstract: AIM: To compare the in vitro activity of the anti-impetigo agent, ozenoxacin, and other antimicrobial agents against Gram-positive clinical isolates from skin and soft tissue infections. MATERIALS & METHODS: Isolates were collected in two studies: 1097 isolates from 49 centers during 2009-2010 and 1031 isolates from ten centers during 2014. Minimum inhibitory concentrations were determined for 18 and 11 antimicrobials in these studies, respectively, using standard broth microdilution methods. Isolates were stratified by species and methicillin susceptibility/resistance and/or levofloxacin susceptibility/nonsusceptibility status. RESULTS: Ozenoxacin exhibited high in vitro activity against Staphylococcus aureus and coagulase-negative staphylococci isolates in both studies. Ozenoxacin was also highly active against Streptococcus pyogenes and Streptococcus agalactiae isolates. CONCLUSION: Ozenoxacin is a potent antimicrobial agent against staphylococci and streptococci.
Note: Reproducció del document publicat a:
It is part of: Future Microbiology, 2018, vol. 13, p. 3-19
Related resource:
ISSN: 1746-0913
Appears in Collections:Articles publicats en revistes (Fonaments Clínics)
Articles publicats en revistes (ISGlobal)

Files in This Item:
File Description SizeFormat 
681196.pdf1.35 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons